# TACE With Dicycloplatin(TP21) in Unresectable HCC

> **NCT05472896** · PHASE3 · UNKNOWN · sponsor: **Gao-jun Teng** · enrollment: 332 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** cTACE
- **DRUG:** Dicycloplatin (TP21)
- **DRUG:** Epirubicin

## Key facts

- **NCT ID:** NCT05472896
- **Lead sponsor:** Gao-jun Teng
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-09
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 332 (ESTIMATED)
- **Last updated:** 2022-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05472896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05472896, "TACE With Dicycloplatin(TP21) in Unresectable HCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05472896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*